Immunoglobulin G
GET
/api/v1/drug/immunoglobulin-gMechanism of action
Sourced from openFDAMechanism-of-action class: Antigen Neutralization.
Indications
Sourced from openFDA- Take 15 minutes before meals.
Dosage & administration
Sourced from openFDADIRECTIONS Adults and children 12 years and older 20 drops in a little water, 2 times per day Children between 12 years and 6 years of age 10 drops in a little water, 2 times per day Children under 6 years 5 drops in a glass of water, 2 times per day
Warnings & precautions
Sourced from openFDAStop use and ask doctor if symptoms persist more than 5 days. If pregnant or breast-feeding ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. Contains ethyl alcohol 30%
FAERS reports
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
19,634 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
- 1Off Label Use4,35322%
- 2Fatigue2,41612%
- 3Drug Ineffective2,39412%
- 4Headache2,21911%
- 5Covid-192,14911%
- 6Sinusitis1,8579.5%
- 7Pneumonia1,8389.4%
- 8Product Dose Omission Issue1,8169.2%
- 9Nausea1,5648.0%
- 10Inappropriate Schedule Of Product Administration1,5497.9%
- 11Malaise1,4957.6%
- 12Pyrexia1,4327.3%
- 13Fall1,3296.8%
- 14Pain1,2766.5%
- 15Illness1,2076.1%
Literature
Recent PubMed references pinned to Immunoglobulin G as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.
- Case Report: Presenting as optic neuritis-a biopsy-proven IgG4 anti-NF155-positive combined central and peripheral demyelination syndrome.Frontiers in immunology · 2026 · Peng Y, Wang X, Zhang W, et al.PMID 42253990DOI 10.3389/fimmu.2026.1793527
- Triple antibody-associated autoimmune encephalitis overlap: a case report of co-existing MOG-IgG, anti-NMDAR, and anti-mGluR5 positivity.Frontiers in immunology · 2026 · Zhao C, Liu J, Zhu L, et al.PMID 42253986DOI 10.3389/fimmu.2026.1848797
- VTX-PID as a novel recombinant immunoglobulin G-degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study.Frontiers in immunology · 2026 · Benichou B, Fuhr R, Vernadal E, et al.PMID 42245647DOI 10.3389/fimmu.2026.1824802
- Serum as a surrogate for salivary IgG: comparison of antigen-specific serum and salivary IgG in sheep.Frontiers in immunology · 2026 · Yeung J, Hannaford R, Wilson T, et al.PMID 42245634DOI 10.3389/fimmu.2026.1797719
- Meet the author: Junyu Xiao.Structure (London, England : 1993) · 2026 · Xiao JPMID 42242184DOI 10.1016/j.str.2026.04.013
- [Clinical profile of patients with secondary immunodeficiency on immunoglobulin replacement therapy].Revista medica del Instituto Mexicano del Seguro Social · 2026 · Méndez-Gómez A, Gómez-Hernández N, Ortega-Cisneros M, et al.PMID 42241293DOI 10.5281/zenodo.19099403
- Correlations between IgG4-related disease, autoimmune pancreatitis, and allergic diseases.Frontiers in immunology · 2026 · Porr C, Vidrighin A, Harris DM, et al.PMID 42238580DOI 10.3389/fimmu.2026.1718303
- Clinical characteristics, management strategies, and outcomes of pediatric immune thrombocytopenic purpura: a five-year single-center experience.European review for medical and pharmacological sciences · 2026 · Kaya ÖS, Kazancı EG, Güven D, et al.PMID 42237958DOI 10.26355/eurrev_202605_37820
Clinical trials
The 10 most recently updated of 1,484 ClinicalTrials.gov registrations naming Immunoglobulin G as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2Enrolling by invitation · Phase 2 · Interventional · 45 enrolled · National Institute of Neurological Disorders and Stroke (NINDS)NCT05350774updated 2026-06-12
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)Recruiting · Phase 2 · Interventional · 461 enrolled · National Cancer Institute (NCI)NCT04546399updated 2026-06-12
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)Recruiting · Phase 3 · Interventional · 1,023 enrolled · Merck Sharp & Dohme LLCNCT07216703updated 2026-06-12
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaRecruiting · Phase 3 · Interventional · 478 enrolled · National Cancer Institute (NCI)NCT06172296updated 2026-06-12
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerRecruiting · Phase 3 · Interventional · 300 enrolled · National Cancer Institute (NCI)NCT04181060updated 2026-06-12
- A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPRecruiting · Phase 3 · Interventional · 218 enrolled · argenxNCT06920004updated 2026-06-12
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerRecruiting · Phase 3 · Interventional · 3,680 enrolled · National Cancer Institute (NCI)NCT06058377updated 2026-06-12
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruiting · Phase 2 · Interventional · 70 enrolled · National Cancer Institute (NCI)NCT03606967updated 2026-06-12
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruiting · Phase 3 · Interventional · 1,875 enrolled · National Cancer Institute (NCI)NCT05675410updated 2026-06-12
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerRecruiting · Phase 3 · Interventional · 255 enrolled · National Cancer Institute (NCI)NCT07198074updated 2026-06-12
Frequently asked questions
- How does Immunoglobulin G work?
- Mechanism-of-action class: Antigen Neutralization.
- What is Immunoglobulin G used for?
- According to FDA labeling, Immunoglobulin G carries indications including: Take 15 minutes before meals.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
- What class of drug is Immunoglobulin G?
- Immunoglobulin G is classified as Antigen Neutralization, Passively Acquired Immunity.
- What are the brand names for Immunoglobulin G?
- Immunoglobulin G is marketed under brand names including Alyglo, Asceniv, Bivigam, Cutaquig, Cuvitru, Flebogamma, GamaSTAN, Gammagard.
Note. Data for
immunoglobulin-g is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.